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Pharmacomechanical thrombectomy for treatment
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and Alan B. Lumsden, MD,a Houston, Tex; and New York, NY
Purpose: The current standard of care for deep venous thromboembolism (DVT) is anticoagulation; however, this
treatment method does not rapidly relieve clot burden or clinical symptoms. We describe a rapid and effective method of
thrombus removal, with simultaneous percutaneous mechanical thrombectomy (PMT) and thrombolysis.
Methods: Over 26 months 20 patients (22 men, 2 women; mean age, 52  6 years [range, 38-79 years]) with extensive
lower extremity DVT were treated with PMT with the AngioJet thrombectomy device in combination with lytic agent
(urokinase, tissue plasminogen activator, or reteplase) added to the infusion. Three patients underwent treatment twice,
because of recurrent DVT. The primary end point was angiographic evidence of restoration of venous patency at
completion of the procedure. Complications, recurrent ipsilateral DVT, and improvement in clinical symptoms were
evaluated.
Results: Complete thrombus removal was obtained in 15 procedures (65%), and partial resolution in the remaining 8
procedures (35%). Inciting occlusive lesions responsible for acute DVT were revealed in 14 patients (61%), and
angioplasty with or without stenting was performed when necessary. In the 8 procedures with partial resolution
additional catheter-directed thrombolysis was carried out on average for 5.7 hours, with further thrombus reduction.
Overall, immediate (<24 hours) improvement in clinical symptoms was noted in 17 patients (74%). There were no
complications related to either PMT or the short duration of lytic agent infusion. At average follow-up of 10.2  0.3
months (range, 3-26 months), 3 patients had recurrent ipsilateral DVT, and underwent repeat treatment.
Conclusions: Addition of lytic agent to PMT facilitates thrombus extraction, decreases overall interventional treatment
time, and improves patient outcomes. In addition, definitive management of underlying anatomic lesions can be
performed in the same setting. Further outcome measures are necessary to study the long-term efficacy of this treatment
method on preservation of valve function, reduction of chronic venous insufficiency, and improved quality of life. ( J Vasc
Surg 2004;40:965-70.)The incidence of deep vein thrombosis (DVT) is approx-
imately 48 per 100,000 persons per year in large community-
based studies, with an in-hospital case-fatality rate from com-
plications of thromboembolism at 12%.1 Venous
thromboembolic disease, including both DVT and pulmo-
nary embolism, is an underdiagnosed medical problem that
results in high rates of significant patient morbidity and mor-
tality. The most common late complication of DVT, post-
thrombotic syndrome, is due to valve damage from chronic
thrombus and intravascular scarring. This may occur months
or years after DVT. Conventional therapy includes anticoag-
ulation with either unfractionated heparin or low molecular
weight heparin, followed by long-term therapy with oral war-
farin sodium.Anticoagulation therapy, the current standardof
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doi:10.1016/j.jvs.2004.08.025care for DVT, only inhibits thrombus propagation and pro-
phylaxis against pulmonary embolism. However, it neither
prevents chronic postthrombotic complications nor removes
existing thrombus.
Endovascular management with percutaneous me-
chanical thrombectomy (PMT) is safe and effective in
reducing thrombus burden.2-5 However, experience
with this therapy is limited. We hypothesize that an
adjunctive measure to PMT, the addition of lytic agent,
is safe and effective, and enables rapid removal of throm-
bus and relief of symptoms from lower extremity DVT
more quickly than does anticoagulation therapy alone.
We present preliminary results of a new technique of
PMT with concomitant lytic therapy for treatment of
venous thrombotic disease.
METHODS
Patients who underwent PMT with adjunctive throm-
bolysis over 26 months were identified from the Division of
Vascular Surgery registry at Baylor College of Medicine,
and the medical records were retrospectively reviewed.
Data collected included patient demographics, DVT risk
factors, periprocedural data, lytic agent used, adjunctive
interventions, and clinical outcomes. All patients were ad-
mitted to the vascular surgery service after identification of
a lower extremity DVT at duplex ultrasound scanning.
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and incapacitating pain. The presence of DVT without
incapacitating pain, despite an edematous limb, was an
indication for standard anticoagulation therapy. Inasmuch
as the design of this study was a retrospective review, no
formal or validated scoring instrument was used to evaluate
symptoms or disability from DVT. Subjective data on clin-
ical condition were abstracted from electronic medical
records. During this period 20 patients with 23 thrombotic
events were identified who had undergone PMT with ad-
junctive lytic therapy. Patients who underwent only PMT
without additional thrombolytic agent were excluded from
the review. No patient chosen for PMT with thrombolysis
had a contraindication to either thrombolysis or anticoag-
ulation therapy. Furthermore, patients with inferior vena
caval thrombus were excluded from data analysis.
Data for 23 lower limbs treated with PMT and lysis
from the authors’ experience were available for analysis.
Mean patient age was 52  6 years (range, 38-79 years).
For the purpose of this study, the age of the thrombus is
defined as the time from diagnosis with duplex ultrasound
scanning to PMT intervention, and was 14 days (range,
0-34 days). Because thrombus age was calculated from the
initial diagnostic duplex ultrasound scan, thrombus was
present for variable amounts of time. Chronic thrombus
potentially contributed to decreased success in some pa-
tients. Furthermore, recurrent ipsilateral DVT after PMT
with lysis were included for review, because they were also
treated with repeat PMT with lysis. All 3 recurrent DVTs
occurred in patients with previously undiagnosed hyperco-
agulable states, which were revealed when they returned
with recurrent DVT. It is not current practice or standard
of care at our institution to order laboratory studies for
hypercoagulable states in a patient with a first DVT or
during the acute thrombotic event.
Preintervention and postintervention venograms were
obtained and graded for degree of thrombus reduction.
Thrombus removal was scored as “complete” if the dictated
procedure report and the venogram demonstrated no re-
sidual thrombus after the procedure. “Partial thrombus
removal” defined those procedures in which any amount of
thrombus remained after the intervention was completed.
We chose not to further separate the amount of remaining
thrombus into groups with estimated percentage clot or
extraction, because it is our belief that any residual throm-
Table I. Thrombolytic agents and dosage for infusion in
pharmacomechanical thrombectomy
Lytic agent Recommended dose
Retaplase 25 mg per 500 mL saline
solution
Tissue-type plasminogen
activator
2-4 units in 50 mL saline
solution
Urokinase 100,000-250,000 U per 500 mL
saline solutionbus may result in valve damage or predilection to recurrentDVT. In addition, this type of measurement from veno-
graphic imaging is operator-dependent and subject to bias.
AngioJet rheolytic thrombectomy system. The An-
gioJet rheolytic thrombectomy system consists of 3 com-
ponents, including a single-use catheter, a single-use pump
set, and a pump drive unit. This system is approved for
peripheral arterial use by the US Food and Drug adminis-
tration. The 6F catheter is available in working lengths of
60, 100, or 120 cm. The catheter is introduced through a
percutaneous approach (6F sheath), and operates over a
0.035-inch guide wire. The catheter design consists of a
lumen that supplies pressurized saline solution to the distal
catheter tip, and a second lumen incorporating the first
lumen, guide wire, and particulate debris removed from
thrombus. The drive unit or pump generates pressure up to
about 10,000 psi (350-450 km/hr) of pulsatile saline so-
lution flow, which exits the catheter tip through multiple
retrograde-directed jets. These high-velocity jets create a
localized low-pressure zone (Bernoulli effect), which leads
to thrombus maceration and aspiration. The jets also pro-
vide the driving force for evacuation of thrombus particu-
late debris through the catheter. The catheter design also
produces radially directed low-velocity fluid recirculation
to dislodge thrombus from the vessel wall and direct
thrombus to the catheter tip for evacuation. The AngioJet
system works in an isovolumetric manner; the saline solu-
tion infusion flow rate (60 mL/min is equal to the evacu-
ation rate of thrombus particulate debris.
In this study a thrombolytic agent of the surgeon’s
choice was added to the infusate. During the period of
review, retaplase (Retavase, Centocor; n 6), recombinant
tissue plasminogen activator (Alteplase, Genentech; n 5),
and urokinase (Abbokinase, Abbott Laboratories; n  12)
were used. The dosing range used and recommended by
the authors is outlined in Table I. In addition, when there
was concern for potential pulmonary embolism during the
procedure, either a removable (n  4) or permanent (n 
3) vena cava filter was placed in selected patients at the
beginning, before PMT, at the discretion of the surgeon.
PMT technique for treatment of DVT. The tech-
niques described represent preferences of the authors,
based on experience, not recommendations from a manu-
facturer. Modification of the AngioJet catheter with a lytic
agent was considered an off-label use of this catheter at the
time of manuscript preparation; thus full informed consent
was obtained from each patient. Recent approval by the US
Food and Drug Administration has been granted. Subse-
quent adjunctive interventions such as endovascular stent-
ing were performed at the judgment of the surgeon.
All PMT procedures were performed in a fully
equipped operating room with capability for endovascular
intervention. Patients were placed in a prone position, and
the ipsilateral popliteal vein was cannulated under ultra-
sound guidance with a micropuncture technique. After the
initial ascending venogram was obtained, the AngioJet
catheter was advanced over a guide wire and through the
thrombosed vein segment. At this point adjunctive throm-
bolytic agent was added to the infusion solution. One slow
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thrombus with lytic agent and aspirate loose thrombus
fragments. The design of the catheter enables thrombus
fragmentation and rapid evacuation through the effluent
lumen. This sequence may be repeated in the event that
significant residual thrombus is seen on subsequent
venograms.
RESULTS
Over 26 months 23 limbs in 20 patients were treated
with this technique. Three cases represent recurrent DVT,
which was treated with repeat PMT and adjunctive lysis.
Identified risk factors for DVT in these patients are listed in
Table II. Twelve limbs had significant ileofemoral throm-
bus burden, and 11 limbs had thrombus confined to the
femoropopliteal segment. Success, defined as complete
thrombus removal, was achieved in 15 of 23 treated limbs
(65%). The remaining 8 limbs (35%) demonstrated varying
degrees of partial thrombus extraction. In 14 limbs (61%)
anatomic lesions in the thrombosed vein were revealed after
PMT. These lesions were thought to contribute to devel-
opment of DVT. In these 14 limbs, combined angioplasty
and stent placement was performed after PMT, for defini-
tive treatment of underlying stenosis (Figs 1 and 2). In the
8 limbs in which initial PMT with adjunctive lysis failed,
catheter-directed thrombolysis was continued on average
for an additional 5.7 hours (range, 2-11 hours). This
additional thrombolytic therapy dramatically improved
thrombus removal in 2 patients. Post intervention, either
subcutaneous low molecular weight heparin or intravenous
unfractionated heparin was continued in all patients. Pa-
tients were subsequently given oral warfarin sodium, the
duration of which was at the discretion of the primary care
physician. In 7 patients with extensive iliofemoral DVT
inferior vena cava filters (removable, n 4; permanent, n
3) were placed before PMT. These 7 patients were among
the 12 patients with iliofemoral DVT. Filters were placed at
the discretion of the surgeon as prophylaxis against pulmo-
nary embolism that might occur during the procedure.
During the latter half of the study the authors preferred to
place retrievable filters, because they offer the option of
removal. Evidence of captured thrombus in the cava filter
was seen on completion venograms in 2 cases (28.5%). No
patient experienced clinical evidence of pulmonary embo-
lism.
Significant clinical improvement was seen in 17 limbs
(74%), as marked by a decrease in pain or swelling of the
affected extremity within 24 hours of treatment. This sub-
jective clinical data was further stratified, on the basis of
medical record documentation of patient well-being, as
dramatic improvement (6 limbs), moderate improvement
(8 limbs), or mild improvement (3 limbs). No clinical
improvement was documented in 26% of limbs. Six patients
required intensive care for a mean of 1.1 days (range, 0-4.2
days). There were 2 minor access site hematomas and 1
retroperitoneal hematoma; however, no surgical interven-
tions or blood transfusions were required for these hemor-
rhagic complications. There were no in-hospital deaths.Follow-up averaged 10.2  0.3 months (range, 13-26
months). There were no deaths during this time. Subse-
quent imaging was incomplete, and was performed in only
5 patients, including the 3 patients with recurrent DVT
who underwent repeat treatment. No meaningful data
could be elucidated from follow-up imaging; thus no doc-
umentation of venous patency or preservation of valve
function was collected in this review.
DISCUSSION
Venous valvular reflux is the dominant cause of chronic
venous insufficiency, with valvular incompetence directly
resulting fromDVT.6 Techniques to preserve venous valves
and restore venous patency should, in theory, decrease
venous hypertension, reducing the incidence and degree of
postthrombotic symptoms. The ability of interventions
such as anticoagulation therapy, thrombolytic therapy, and
surgical or endovascular thrombectomy to restore venous
patency, remove obstruction, and ultimately decrease the
incidence and severity of reflux in a diseased extremity can
be used to return patients to their normal way of life.
However, no therapeutic options or interventions to date
have demonstrated superiority over anticoagulation ther-
apy. Consequently, anticoagulation remains the standard of
care while new methods are being evaluated.
It is hypothesized that rapid relief of thrombus burden by
directly extracting thrombus surgically orwith lytic therapy, or
a combination of the 2 methods, should decrease the risk for
pulmonary embolism andpostthrombotic syndrome resulting
inmanifestations of chronic venous insufficiency. As a result of
the hemorrhagic complications associated with catheter-di-
rected thrombolysis, PMT has emerged as a useful option for
treatment of acute DVT. Various thrombectomy catheters
with different mechanisms of clot removal are commercially
available; full discussion of each of these catheters is beyond
the scope of this article. The catheters fall into 1of 2 categories
for clot extraction mechanism: microfragmentation or
thrombo-aspiration (Venturi effect). Several PMT catheters
may be used in combination with adjunctive thrombolytic
agents for more complete and rapid thrombus removal. The
combination of therapies enables lower mean dosage and
duration of lytic infusion. Reducing the dosage or time for
Table II. Risk factors for venous thrombosis (23 cases,
20 patients)
Risk factors n
Malignancy 5
Hypercoagulable state 3
May-Thurner syndrome 4
Immobilization 3
Previous ipsilateral DVT* 3
Other stenosis 2
Idiopathic 5
DVT, Deep venous thrombosis.
*Three patients in this series received treatment and then had recurrent
DVT.complete thrombolysis should translate into reducedmorbid-
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thermore, underlying anatomic lesions that precipitated the
thrombotic event may be unmasked with PMT, with or with-
out adjunctive lysis. Venous stenoses can be treated after
thrombectomy at the same setting, as evidenced in 61% of our
cases, resulting in more efficient patient care.
Several authors have evaluated multiple PMT catheters
in the treatment of DVT. However, to date there are no
prospective, randomized trial data available or large-scale
clinical series. The AngioJet thrombectomy device has no
direct contact with the vessel wall, thus causing only mini-
mal endothelial denudation.7 Because thrombus removal is
not produced by the actual mechanical force of the infusion
solution, but by an indirectly created negative pressure
zone, risk for luminal endothelial damage is minimal. By
maintaining the structural integrity of the native venous
endothelium, viability and the anti-thrombotic activities of
the intact endothelium are preserved. Nonetheless, pro-
longed contact time between thrombus and endothelium
increases endothelial damage.8 In a retrospective review of
themanagement of DVT, Kasirajan et al4 demonstrated the
efficacy of the AngioJet PMT system in thrombus removal,
venous patency restoration, and relief of symptoms. In that
study, more than 90% thrombus clearance with PMT alone
was achieved in only 4 patients (23.5%). Adjunctive throm-
bolytic agents were used after unsatisfactory PMT in 9 of 17
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Fig 1. A and B, Initial ascending venograms demonstrate com-
plete occlusion of common femoral vein, iliac veins, and proximal
superficial femoral vein. C, Venogram obtained after pharmaco-
mechanical thrombectomy with AngioJet catheter and adjunctive
lytic agent added to infusion solution. Stenosis was revealed in the
Fig 2. Completion venogram shows no residual thrombus and
excellent flow into the inferior vena cava.common iliac vein.
ng low
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PMT catheter. Improvement in clinical symptoms was
noted in 82% of patients over 11-month follow-up.
PMTwith added lytic agents restores venous patency in
the operating room or intervention suite, obviating the
need for intensive care unit stays or multiple transfers for
repeat venography. Furthermore, lower total dosage and
decreased infusion time of thrombolytic agents were used
than with catheter-directed thrombolysis alone. This syn-
ergistic treatment method resulted in lower overall cost and
reduction in hemorrhagic complications in this limited
study. Moreover, adjunctive endovascular techniques, such
as balloon angioplasty with or without stent placement,
were successfully performed in the same setting of PMT.
In this preliminary study inferior vena cava filters were
placed at the discretion of the treating surgeon. Retrievable
inferior vena cava filters are efficacious in preventing pul-
monary embolus and in trapping embolus. However, con-
troversy remains as to use of filters as a prophylactic inter-
vention.8-10 We have seen no associated complications,
such as insertion site thrombosis, filter migration, or vena
cava injury. In addition, the removable filters were success-
fully retrieved. The window for removal, however, has been
short (2 weeks), but newer filters are available that allow a
longer time frame for placement. After review of our results
Fig 3. Treatment algorithm for treatifor PMT with lytic agent for DVT, as well as the use oftemporary filter protection, we developed a treatment al-
gorithm (Fig 3).
There are limitations to our study. This report is a
retrospective observational analysis of patients who under-
went treatment with a new technique for venous thrombus
extraction. Randomization or direct comparisons between
mechanical thrombectomy with lysis to mechanical throm-
bectomy alone were not part of this limited preliminary
study. Although we are encouraged by the excellent out-
comes presented, we cannot be absolutely certain that the
lytic agent conferred additional benefit to PMT. The need
for inferior vena cava filters and adjunctive therapy such as
angioplasty were at the discretion of the surgeons perform-
ing the individual procedures. Routine follow-up duplex
ultrasound scanning was not performed to assess venous
patency and valve function or to document recurrent
thrombotic events.
Symptoms and procedural success were derived from
the clinical notes in the medical record; thus disparities may
exist in reporting. In our series there were 39% of patients
with partial thrombus extraction and 29% of patients with-
out improvement of symptoms. This relatively high failure
rate may be related to the age of the thrombus at presenta-
tion. It was difficult to ascertain the true age of thrombus,
because of delay in obtaining imaging studies, diagnosis,
er extremity deep venous thombosis.and late presentation of some patients. However, the find-
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success that can be achieved with this technique of throm-
bus removal. Based on a complete review of our data as
presented, we have refined our clinical practice and recom-
mend a treatment algorithm. We will base future prospec-
tive comparative analysis on this algorithm, and also include
a validated outcomes measurement tool for venous severity
scoring before and after intervention.
CONCLUSIONS
PMT with the AngioJet thrombectomy catheter with
concomitant thrombolysis is a new use of existing technol-
ogies that should promote more rapid and complete
thrombus extraction over standard therapy (anticoagula-
tion). In theory, early and rapid thrombus removal should
preserve venous valve patency. Only long-term prospective
randomized studies comparing this technique with me-
chanical thrombectomy alone or with standard anticoagu-
lation therapy will provide definitive data to support our
supposition. Patient selection is critical, because in those
with older thrombus complete thrombus extraction may
not be achieved. We advocate serial follow-up duplex scan-
ning to document freedom from recurrent DVT and valve
function. This new technique will add to those available to
the endovascular surgeon.
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